Rituximab treatment of cyclophosphamide-resistant patients with ANCA-associated vasculitis

Rituximab treatment of cyclophosphamide-resistant patients with ANCA-associated vasculitis - RiCRAV

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000906

Enrollment

Registered

2007-12-01

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-associated vasculitis

Interventions

Weekly infusion of Rituximab 375mg per square meter for 4 times plus oral daily prednisolone 0.5-1mg/kg for 2 weeks and tapered.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fulfil the classification criteria of either Wegener's granulomatosis or microscopic polyangiitis based on the Ministry of Health, Labor and Welfare of Japan, and satisfy one of the following criteria; A, failed to induce remission after 6 months of cyclophosphamide therapy. B, relapsed within 1 year of remission induction therapy with cyclophosphamide. C, difficult to repeat cyclophosphamide because of adverse reaction.

Exclusion criteria

Exclusion criteria: 1. severe infection (including tuberculosis, HCV, HBV and HIV). 2. history of hypersensitivity to mouse-derived protein 3. congestive heart failure with NYHA III or IV

Design outcomes

Primary

Measure	Time frame
complete remission at 12 months	—

Secondary

Measure	Time frame
adverse events, BVAS/WG, VDI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026